A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD).
Bystritsky A, Kerwin L, Feusner JD.
Department of Psychiatry, Faculty of California, CA, Los Angeles, USA. abystritskymednet.ucla.edu
BACKGROUND: Rhodiola rosea is actually an herbal dietary supplement a large number of in the overall public of Russian federation & anywhere else in the planet have utilized for many years to alleviate common anxiety, depression, and insomnia. Whether or not R. rosea works well in reducing symptoms that are the same in clinical samples is unfamiliar.
The objective of this particular pilot study was evaluating if R. rosea works well in reducing symptoms of generalized anxiety disorder (GAD). METHOD: 10 (ten) participants with a DSM IV examination of GAD, recruited out of the UCLA Anxiety Disorders Program and between the ages of thirty four as well as fifty five, were enrolled in this specific study from November 2005 to May 2006. Participants got a full daily serving of 340 mg of R. rosea extract for ten weeks.
Assessments provided the Hamilton Anxiety Rating Scale (HARS), the Four Dimensional Anxiety as well as Depression Scale, as well as the Clinical Global Impressions of Severity/Improvement agen poker terpercaya. RESULTS: Individuals addressed with R. rosea showed considerable decreases in mean HARS scores at endpoint (t=3.27, p=0.01). Adverse events had been moderate or mild generally in seriousness, the most typical being dry mouth as well as dizziness. CONCLUSIONS: Significant improvement of GAD symptoms was discovered with R. rosea, with a decrease in HARS scores much like which present in clinical trials. These preliminary results warrant additional exploration of therapy with R. rosea in clinical samples.
Clinical trial of Rhodiola rosea L. extract SHR 5 in the therapy of mild to moderate depression.
Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A.
Department of Neurology, Armenian State Medical Faculty, Yerevan, Armenia.
The goal of this particular analysis was to evaluate the efficacy as well as safety of standardized extract SHR 5 of rhizomes of Rhodiola rosea L. in individuals being affected by a present episode of mild/moderate depression. The stage III clinical trial was carried out as a randomized double blind placebo controlled research with parallel groups more than six weeks.
Participants, males as well as females aged 18 70 years, were selected based on DSM IV diagnostic criteria for depression, the severity of that was influenced by scores acquired in Beck Depression Inventory as well as Hamilton Rating Scale for Depression (HAMD) questionnaires. Individuals with first HAMD scores between twenty one as well as thirty one were randomized into 3 groups, certainly one of which (group A: thirty one individuals) received 2 tablets every day of SHR 5 (340 mg/day), a second (group B: twenty nine individuals) received 2 tablets two times each day of SHR 5 (680 mg/day), along with a third (group C: twenty nine patients) received 2 placebo tablets every day.
The efficacy of SHR 5 extract with regard to depressing complaints was evaluated on days zero as well as forty two of the study period from specific and total subgroup HAMD scores. For people in organizations A and B, total depression, along with insomnia, mental instability as well as somatization, however, not self esteem, improved substantially following medication, whilst the placebo group didn’t present these kinds of improvements. No significant side effects had been described in any of the organizations A C.
It’s concluded that the standardized extract SHR 5 shows anti depressive potency of individuals with gentle to moderate depression when administered in dosages of either 340 or maybe 680 mg/day with a 6 week period.Efficacy as well as tolerability of a Rhodiola rosea extract of adults with cognitive and physical deficiencies.